Aurinia Pharmaceuticals Inc. (AUPH)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Aurinia Pharmaceuticals Inc. reported revenue of $283.06M, up 20.4% from the prior year. The company was profitable, with a net margin of 101.5%. It held $751.59M in total assets against $170.26M in total liabilities.
Key ratios (FY2025)
37.1%
Operating margin
101.5%
Net margin
49.4%
Return on equity
+20.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M | $318.0K | $463.0K | — |
| Cost of Revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M | $0 | $0 | — | — |
| Operating Income | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M | -$90.94M | -$55.24M | — |
| Net Income | $287.20M | $5.75M | -$78.02M | -$108.18M | -$180.97M | -$102.68M | -$88.39M | -$53.08M | — |
| EPS (Diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-0.95 | — | — |
| Total Assets | $751.59M | $550.64M | $548.06M | $470.86M | $543.37M | $463.66M | $324.30M | — | — |
| Total Liabilities | $170.26M | $173.17M | $170.11M | $65.42M | $64.28M | $55.91M | $25.70M | — | — |
| Shareholders' Equity | $581.33M | $377.48M | $377.95M | $405.44M | $479.09M | $407.75M | $298.60M | $135.72M | $177.92M |
| Cash & Equivalents | $80.16M | $83.40M | $48.76M | $94.09M | $231.64M | $272.35M | $306.02M | — | — |
| Operating Cash Flow | $135.66M | $44.39M | -$33.46M | -$79.53M | -$157.69M | -$69.86M | -$63.59M | -$51.61M | — |
| Shares Outstanding | 132.32M | 140.88M | 143.83M | 142.27M | 141.60M | 126.70M | 111.80M | 85.50M | — |